Skip Nav Destination
Issues
1 February 2013
-
Cover Image
Cover Image
In silico molecular modeling of the EGFR exon 20 A763_Y764 insertion mutation. Mutations in this region are predicted to cause significant rearrangement of the C helix (yellow) but do not affect the erlotinib binding pocket directly (erlotinib shown in green). Insertions in EGFR exon 20 that are more distal (3′) are expected to result in a greater obstructive effect on erlotinib binding. These predictions suggest a basis for the observed variability of response to EGFR inhibition in patients with different types of EGFR exon 20 insertions. For details, see article by Arcila and colleagues on page 220. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Current Preclinical Models for the Advancement of Translational Bladder Cancer Research
David J. DeGraff; Victoria L. Robinson; Jay B. Shah; William D. Brandt; Guru Sonpavde; Yibin Kang; Monica Liebert; Xue-Ru Wu; John A. Taylor, III; for the Translational Science Working Group of the Bladder Advocacy Network Think Tank
Chemical Therapeutics
The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts
Ezia Bello; Giulia Taraboletti; Gennaro Colella; Massimo Zucchetti; Daniele Forestieri; Simonetta A. Licandro; Alexander Berndt; Petra Richter; Maurizio D'Incalci; Ennio Cavalletti; Raffaella Giavazzi; Gabriella Camboni; Giovanna Damia
VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
Stefan Hart; Veronica Novotny-Diermayr; Kee Chuan Goh; Meredith Williams; Yong Cheng Tan; Lai Chun Ong; Albert Cheong; Bee Kheng Ng; Chithra Amalini; Babita Madan; Harish Nagaraj; Ramesh Jayaraman; Khalid M. Pasha; Kantharaj Ethirajulu; Wee Joo Chng; Nurulhuda Mustafa; Boon Cher Goh; Cyril Benes; Ultan McDermott; Mathew Garnett; Brian Dymock; Jeanette M. Wood
Cancer Therapeutics Insights
Companion Diagnostics and Biomarkers
Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins
Hiroyuki Sumi; Masato Yabuki; Kenichi Iwai; Megumi Morimoto; Ryosuke Hibino; Masakazu Inazuka; Kentaro Hashimoto; Yohei Kosugi; Kazunobu Aoyama; Shunsuke Yamamoto; Mie Yoshimatsu; Hideki Yamasaki; Ryuichi Tozawa; Tomoyasu Ishikawa; Sei Yoshida
Correction
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.